HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peter J Houghton Selected Research

alteichin

12/2021Altertoxin II, a Highly Effective and Specific Compound against Ewing Sarcoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Peter J Houghton Research Topics

Disease

183Neoplasms (Cancer)
02/2022 - 07/2002
34Rhabdomyosarcoma
01/2022 - 04/2002
28Ewing Sarcoma (Sarcoma, Ewing)
02/2022 - 08/2007
26Neuroblastoma
01/2020 - 09/2002
24Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2019 - 02/2006
22Osteosarcoma (Osteogenic Sarcoma)
01/2022 - 10/2005
22Sarcoma (Soft Tissue Sarcoma)
11/2021 - 04/2008
19Leukemia
12/2019 - 08/2007
11Wilms Tumor (Wilm's Tumor)
01/2021 - 12/2003
10Hypoxia (Hypoxemia)
01/2022 - 12/2004
10Brain Neoplasms (Brain Tumor)
01/2022 - 09/2002
9Rhabdoid Tumor (Rhabdoid Tumors)
01/2021 - 05/2008
7Glioblastoma (Glioblastoma Multiforme)
10/2015 - 06/2008
7Alzheimer Disease (Alzheimer's Disease)
01/2012 - 03/2004
6Glioma (Gliomas)
01/2022 - 07/2002
6Alveolar Rhabdomyosarcoma
01/2019 - 03/2008
5Medulloblastoma
02/2015 - 08/2004
5Breast Neoplasms (Breast Cancer)
10/2009 - 12/2003
4Colonic Neoplasms (Colon Cancer)
01/2021 - 08/2009
4Neoplasm Metastasis (Metastasis)
01/2020 - 01/2006
4Cognitive Dysfunction
01/2016 - 01/2003
4Astrocytoma (Pilocytic Astrocytoma)
10/2015 - 01/2006
4Diarrhea
08/2012 - 07/2002
3Tuberous Sclerosis (Bourneville's Disease)
01/2022 - 02/2008
3Thrombocytopenia (Thrombopenia)
12/2019 - 04/2015
3Genetic Translocation (Chromosomal Translocation)
11/2017 - 11/2014
3Lymphoma (Lymphomas)
07/2013 - 03/2006
3Disease Progression
01/2012 - 06/2005
3Carcinoma (Carcinomatosis)
06/2008 - 04/2002
2Drug-Related Side Effects and Adverse Reactions
12/2019 - 08/2009
2Embryonal Rhabdomyosarcoma
01/2019 - 07/2007

Drug/Important Bio-Agent (IBA)

45N- propyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (PPTP)IBA
01/2021 - 12/2007
33Pharmaceutical PreparationsIBA
12/2021 - 09/2002
18Irinotecan (Camptosar)FDA LinkGeneric
01/2020 - 07/2002
17Sirolimus (Rapamycin)FDA Link
01/2022 - 04/2002
16Proteins (Proteins, Gene)FDA Link
01/2022 - 12/2003
13Mechanistic Target of Rapamycin Complex 1IBA
01/2022 - 02/2008
10Cytotoxins (Cytolysins)IBA
12/2021 - 08/2007
10Vincristine (Oncovin)FDA LinkGeneric
01/2020 - 08/2007
9DNA (Deoxyribonucleic Acid)IBA
02/2022 - 09/2002
9TOR Serine-Threonine KinasesIBA
01/2018 - 04/2002
9Topotecan (Hycamtin)FDA LinkGeneric
11/2013 - 02/2003
8Biomarkers (Surrogate Marker)IBA
01/2021 - 03/2010
8Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2014 - 05/2007
7Temozolomide (Temodar)FDA LinkGeneric
02/2022 - 09/2002
7LigandsIBA
11/2020 - 10/2009
7Phosphotransferases (Kinase)IBA
01/2020 - 02/2008
6ProdrugsIBA
01/2021 - 09/2002
6EnzymesIBA
02/2018 - 07/2002
6Cisplatin (Platino)FDA LinkGeneric
02/2018 - 05/2008
5RNA (Ribonucleic Acid)IBA
02/2022 - 10/2014
5Messenger RNA (mRNA)IBA
01/2022 - 02/2012
5Immunoconjugates (Immunoconjugate)IBA
01/2022 - 04/2013
5EWS-FLI fusion proteinIBA
01/2021 - 03/2008
5CamptothecinIBA
01/2020 - 12/2003
5Antineoplastic Agents (Antineoplastics)IBA
12/2019 - 05/2003
5Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2019 - 09/2002
4talazoparibIBA
02/2022 - 01/2015
4Insulin-Like Growth Factor II (Somatomedin A)IBA
01/2022 - 03/2012
4Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2022 - 12/2013
4Small Interfering RNA (siRNA)IBA
01/2020 - 09/2008
4navitoclaxIBA
12/2019 - 06/2008
4Histone Deacetylase InhibitorsIBA
01/2019 - 01/2006
4Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2016 - 12/2004
4AntibodiesIBA
12/2015 - 03/2012
4cixutumumabIBA
12/2015 - 07/2010
4temsirolimusFDA Link
04/2015 - 08/2003
4Insulin-Like Growth Factor I (IGF-1)IBA
06/2013 - 01/2003
4Cholinergic Agents (Cholinergics)IBA
10/2008 - 01/2003
4Eukaryotic Initiation Factor-4EIBA
09/2008 - 04/2002
3Sorafenib (BAY 43-9006)FDA Link
01/2020 - 08/2009
3Biological ProductsIBA
12/2019 - 08/2010
3MLN 8237IBA
01/2019 - 07/2010
3Transcription Factors (Transcription Factor)IBA
11/2017 - 01/2014
3(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA
06/2017 - 02/2012
3Taxoids (Taxanes)IBA
11/2015 - 10/2005
3Antimitotic AgentsIBA
07/2015 - 10/2005
3Insulin-Like PeptidesIBA
02/2015 - 06/2008
3Angiogenesis InhibitorsIBA
11/2014 - 09/2012
3Insulin (Novolin)FDA Link
06/2013 - 06/2006
3Gefitinib (Iressa)FDA Link
08/2012 - 10/2004
3Somatomedin Receptors (Somatomedin Receptor)IBA
05/2012 - 10/2009
3FlavonoidsIBA
01/2012 - 03/2007
3Phosphatidylinositols (Phosphatidylinositol)IBA
08/2011 - 01/2003
3Type I DNA Topoisomerases (Topoisomerase I)IBA
05/2010 - 09/2002
3EverolimusFDA Link
03/2010 - 08/2003
3Acetylcholine (Acetylcholine Chloride)FDA Link
04/2007 - 11/2004
3AcetylcholinesteraseIBA
04/2007 - 03/2004
2Alkylating AgentsIBA
02/2022 - 09/2008
2Membrane Proteins (Integral Membrane Proteins)IBA
01/2022 - 09/2021
2trametinibIBA
01/2022 - 01/2022
2Histones (Histone)IBA
11/2021 - 01/2006
2Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2021 - 02/2015
2ChromatinIBA
01/2021 - 01/2018
2tazemetostatIBA
01/2021 - 01/2017
2CytokinesIBA
11/2020 - 01/2012
2eribulinFDA Link
01/2020 - 08/2013

Therapy/Procedure

45Therapeutics
02/2022 - 07/2002
11Drug Therapy (Chemotherapy)
11/2021 - 09/2002
8Radiotherapy
11/2021 - 02/2006